Type of AML-M3 - Acute promyelocytic leukemia (APL) Posts on Medivizor
Navigation Menu

Type of AML-M3 – Acute promyelocytic leukemia (APL) Posts on Medivizor

Is an alternative, chemotherapy-free approach possible for patients with acute promyelocytic leukemia?

Is an alternative, chemotherapy-free approach possible for patients with acute promyelocytic leukemia?

Posted by on Apr 30, 2023 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness of treatment with all-trans retinoic acid (ATRA; Retin-a) and arsenic trioxide (ATO; Trisenox) to ATRA-ATO with chemotherapy (CHT) in patients with newly diagnosed acute promyelocytic leukemia (APL). The data showed that treatment with ATRA-ATO was equally effective as ATRA-ATO plus CHT in these...

Read More

How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?

How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?

Posted by on Oct 17, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the treatment effects of all-trans retinoic acid (ATRA; Vesanoid) and arsenic trioxide (ATO; Trisenox), compared to ATRA with standard chemotherapy on long-term health-related quality of life (HRQoL) in patients with acute promyelocytic leukemia (APL). The data showed better long-term HRQoL measures in patients treated...

Read More

Treating patients with high risk acute promyelocytic leukemia (APL) with ATRA, arsenic trioxide and gemtuzumab ozogamicin

Posted by on May 10, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the effectiveness and safety of combing all-trans retinoic acid (ATRA; Vesanoid), arsenic trioxide (ATO; Trisenox), and gemtuzumab ozogamicin (GO; Milotarg) in treating patients with high risk (HR) acute promyelocytic leukemia (APL). The authors found that the combination therapy was effective and well...

Read More